Hederagenin is an orally active triterpenoid saponin with antitumor activity. It inhibits LPS-induced iNOS, COX-2, and NF-κB expression in cells. Hederagenin also increases ROS production in cancer cells, disrupts mitochondrial membrane potential, and induces apoptosis. It sensitizes cancer cells to Cisplatin and Paclitaxel, enhancing apoptosis, and shows preventive potential against alcoholic liver injury.
- Home
- Solutions
- By Disease
- Systemic Mitochondrial Disease
- Alpers Disease
- Barth Syndrome
- Carnitine Deficiency
- Creatine Deficiency Syndromes
- Co-Enzyme Q10 Deficience
- Friedreich’s Ataxia
- Kearns-Sayre Syndrome
- Lactic Acidosis
- Leigh Syndrome
- Mitochondrial DNA Depletion Syndrome
- MELAS Syndrome
- Multiple Mitochondrial Dysfunction Syndrome
- Short-Chain Acyl-CoA Dehydrogenase Deficiency
- Thymidine Kinase 2 Deficiency
- Mitochondrial Neurogastrointestinal Encephalopathy
- Organ-specific Mitochondrial Diseases
- Systemic Mitochondrial Disease
- By Applications
- Mitochondrial Disease Diagnostics Service
- Therapeutics Development Services for Mitochondrial Diseases
- Mitochondrial Disease Target Development & Identification Service
- Mitochondrial Disease Model Development Service
- Drug Development Service for Mitochondrial Diseases
- In Vitro Mitochondrial Analysis Service
- In Vivo Mitochondrial Fission and Fusion Analysis
- By Molecular Type
- By Disease
- Products
- Mitochondrial Isolation Reagents & Kits
- Mitochondrial Staining Reagents & Kits
- Mitochondrial Disease Diagnostic Reagents & Kits
- Biochemical Inhibitors & Activators
- Mitochondrial Specific Antibodies
- Mitochondrial Recombinant Proteins
- Mitochondria Related Peptides
- Natural Products Targeting Mitochondria
- Resource
- About Us
- Contact Us
- Careers